Literature DB >> 19856228

Plurifocal malignant peripheral nerve sheath tumor demonstrated by 18F-fluorodeoxyglucose positron emission tomography/computed tomography.

Francesco Bertagna1, Giovanni Bosio, Giorgio Biasiotto, Giordano Savelli, Carlo Rodella, Raffaele Giubbini, Josh Rosenbaum, Abass Alavi.   

Abstract

Malignant peripheral nerve sheath tumors (MPNSTs) are sarcomas that derive from peripheral nerves or from cells associated with the nerve sheath. Magnetic resonance imaging is the main diagnostic imaging modality for evaluating MPNSTs. Computed tomography (CT) of the chest is the main imaging modality used to screen for distant disease, and bone scanning is considered useful for identifying selected metastases. Fluorodeoxyglucose positron emission tomography (FDG-PET) has been useful for differentiating malignant nerve sheath tumors from benign lesions and appears to be able to forecast prognosis. We report a case of a patient with neurofibromatosis 1 (NF1) with a histological diagnosis of MPNST, which was diagnosed by biopsy of a posterior right thigh mass examined by (18)F-FDG-PET/CT.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19856228     DOI: 10.1007/s11604-009-0343-2

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  10 in total

1.  The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression.

Authors:  Michael J Fisher; Sandip Basu; Eva Dombi; Jian Q Yu; Brigitte C Widemann; Avrum N Pollock; Avital Cnaan; Hongming Zhuang; Peter C Phillips; Abass Alavi
Journal:  J Neurooncol       Date:  2007-12-11       Impact factor: 4.130

2.  Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases.

Authors:  B S Ducatman; B W Scheithauer; D G Piepgras; H M Reiman; D M Ilstrup
Journal:  Cancer       Date:  1986-05-15       Impact factor: 6.860

3.  FDG-PET/CT findings of sarcomatous transformation in neurofibromatosis: a case report.

Authors:  Hideki Otsuka; Michael M Graham; Akiko Kubo; Hiromu Nishitani
Journal:  Ann Nucl Med       Date:  2005-02       Impact factor: 2.668

4.  Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.

Authors:  R E Ferner; J D Lucas; M J O'Doherty; R A Hughes; M A Smith; B F Cronin; J Bingham
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-03       Impact factor: 10.154

Review 5.  Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis.

Authors:  J M Woodruff
Journal:  Am J Med Genet       Date:  1999-03-26

6.  International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis.

Authors:  Rosalie E Ferner; David H Gutmann
Journal:  Cancer Res       Date:  2002-03-01       Impact factor: 12.701

7.  [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1.

Authors:  Victoria S Warbey; Rosalie E Ferner; Joel T Dunn; Eduardo Calonje; Michael J O'Doherty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-14       Impact factor: 9.236

8.  Neurofibroma with increased uptake of [F-18]-fluoro-2 deoxy-D-glucose interpreted as a metastatic lesion.

Authors:  Chung-Huei Hsu; Chi-Ming Lee; Fong-Chieh Wang; Chia-Lang Fang
Journal:  Ann Nucl Med       Date:  2003-10       Impact factor: 2.668

9.  Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.

Authors:  Gunnar Johansson; Yonatan Y Mahller; Margaret H Collins; Mi-Ok Kim; Takahiro Nobukuni; John Perentesis; Timothy P Cripe; Heidi A Lane; Sara C Kozma; George Thomas; Nancy Ratner
Journal:  Mol Cancer Ther       Date:  2008-05       Impact factor: 6.261

10.  [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.

Authors:  R E Ferner; J F Golding; M Smith; E Calonje; W Jan; V Sanjayanathan; M O'Doherty
Journal:  Ann Oncol       Date:  2007-10-11       Impact factor: 32.976

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.